Naramig (Naratriptan)

Naratriptan, the active ingredient in Naramig, is a Triptan presented as an oral formulation for oral use. It selectively targets serotonin receptors to alleviate acute migraine attacks in adult patients, providing relief from headache and associated symptoms.

GNH USA supplies Naramig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and offering reliable global distribution.

Naratriptan is indicated for the acute treatment of migraine, a vascular headache disorder.

Acute migraine attacks: rapid relief of headache pain and associated nausea or photophobia. Migraine without aura: reduction of attack severity when taken at onset. Migraine with aura: alleviation of the headache phase following aura symptoms.

Common adverse reactions to Naratriptan are generally mild and transient, while rare events may require medical attention.

Common Side Effects: - Dry mouth - Drowsiness - Nausea - Chest tightness

Serious or Rare Side Effects: - Cardiovascular events such as myocardial ischemia - Serotonin syndrome, especially with other serotonergic agents - Severe allergic reactions, including anaphylaxis

Before prescribing Naratriptan, clinicians should evaluate patient history and comorbid conditions. - Cardiovascular disease: avoid use in patients with uncontrolled hypertension or coronary artery disease. - History of stroke: contraindicated in individuals with prior cerebrovascular events. - Concomitant serotonergic drugs: risk of serotonin syndrome; monitor closely. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Naratriptan may interact with several drug classes, requiring caution.

Major Interactions (Avoid): - Ergot alkaloids: combined use may cause severe vasospasm. - MAO inhibitors: increased risk of hypertensive crisis. - SSRIs/SNRIs: heightened chance of serotonin syndrome. - Other triptans: additive vasoconstrictive effect.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance hypotensive effect. - Antihypertensives: monitor blood pressure. - CYP1A2 inhibitors (e.g., fluvoxamine): may increase naratriptan plasma levels.